AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28197031 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg oral diclofenac 1 hour before procedure (Group A)
Number of subjects: 121
Study 28197031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 121
Study 28197834 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313
Study 28197834 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313
Study 28197834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study 28197843 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin measurement upon presentation to the emergency department
Number of subjects: 391
Study 28197843 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin measurement after adjusting for age > 50, focal-neurological abnormalities, and thunderclap onset of symptoms
Number of subjects: 391
Study 28197843 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin measurement in relation to the multivariate logistic clinical model
Number of subjects: 391
Study 28197843 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin values in patients reaching the secondary endpoint
Number of subjects: 391
Study 28197931 — intervention group
Group type: COMPARATOR
Intervention: LSD 100 µg
Number of subjects: 40
Study 28197931 — intervention group
Group type: COMPARATOR
Intervention: LSD 200 µg
Number of subjects: 40
Study 28197931 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 100 µg and 200 µg
Number of subjects: 40
Study 28197979 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-CA 4 g once daily from day 8 to day 28
Number of subjects: 78
Study 28197979 — intervention group
Group type: COMPARATOR
Intervention: OM3-CA 4 g
Number of subjects: 78
Study 28197979 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg plus ASA 81 mg once daily for 14 days
Number of subjects: 78
Study 28199472 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare RAAS variants
Number of subjects: 600
Study 28199472 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare APLN variants
Number of subjects: 600
Study 28199472 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele of rs78377269
Number of subjects: 600
Study 28199478 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carmustine and intravenous O6-benzylguanine
Number of subjects: 17
Study 28199478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-dose O6-benzylguanine plus carmustine
Number of subjects: 17
Study 28199478 — intervention group
Group type: COMPARATOR
Intervention: Single-dose O6-benzylguanine and carmustine
Number of subjects: 17
Study 28199523 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cerebral microemboli (ME)
Number of subjects: 50
Study 28199523 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cerebral microemboli (ME)
Number of subjects: 50
Study 28199523 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative solid ME
Number of subjects: 50
Study 28199523 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative solid ME
Number of subjects: 50
Study 28199523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral blood flow velocity (CBFV)
Number of subjects: 50
Study 28199523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral tissue oxygen index
Number of subjects: 50
Study 28199816 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoch 1 (2000-2003)
Number of subjects: 4458
Study 28199907 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived genetic influences on eating behavior
Number of subjects: 261
Study 28199907 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic attributions for eating behaviors
Number of subjects: 261
Study 28202056 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml 12.6% carbohydrate-rich drink
Number of subjects: 9
Study 28202056 — intervention group
Group type: COMPARATOR
Intervention: Gender-matched reference group (elective hip replacement patients)
Number of subjects: 9
Study 28202056 — intervention group
Group type: COMPARATOR
Intervention: Gender-matched reference group (healthy volunteers)
Number of subjects: 9
Study 28202638 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Dose Supplementation
Number of subjects: 0
Study 28202638 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian Rhythm
Number of subjects: 0
Study 28202638 — intervention group
Group type: EXPERIMENTAL
Intervention: Time within Feed
Number of subjects: 0
Study 28202705 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral intervention for tics (CBIT)
Number of subjects: 248
Study 28202705 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation and supportive therapy (PST)
Number of subjects: 248
Study 28203424 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with paclitaxel and cisplatin plus McKeown esophagectomy with total two-field lymphadenectomy
Number of subjects: 528
Study 28203424 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 528
Study 28203475 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin-Down Maneuver
Number of subjects: 0
Study 28203475 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28203689 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-to-day SBP variability parameters (SD, CV, Δ SBP)
Number of subjects: 229
Study 28203689 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-to-day Δ SBP
Number of subjects: 229
Study 28203689 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-to-day Δ SBP (after adjusting for mean SBP)
Number of subjects: 229
Study 28204448 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR measured myocardial perfusion reserve (MPR)
Number of subjects: 174
Study 28204448 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise testing (ETT)
Number of subjects: 174
Study 28204448 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR
Number of subjects: 174
Study 28204448 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing
Number of subjects: 174
Study 28204544 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-tilmanocept
Number of subjects: 2
Study 28204544 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-infected subjects
Number of subjects: 2
Study 28204544 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 2
Study 28204726 — intervention group
Group type: EXPERIMENTAL
Intervention: Qutenza® (topical capsaicin 8%)
Number of subjects: 20
Study 28205030 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-port robotic distal gastrectomy (RRDG)
Number of subjects: 19
Study 28205038 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine for inhalation
Number of subjects: 0
Study 28205039 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart (0.2 U/kg)
Number of subjects: 218
Study 28205039 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (IAsp) (0.2 U/kg)
Number of subjects: 218
Study 28205231 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA detection in plasma samples from metastatic pancreatic cancer patients
Number of subjects: 188
Study 28205231 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA presence monitoring after chemotherapy
Number of subjects: 188
Study 28205231 — intervention group
Group type: EXPERIMENTAL
Intervention: ERBB2 exon17 mutation
Number of subjects: 188
Study 28207430 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre with manual holding of the rebreathing bag and constant airway pressure of 30 cmH2O for 10 s before fluid loading
Number of subjects: 49
Study 28207430 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PPVauto
Number of subjects: 49
Study 28207430 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PPVmanual
Number of subjects: 49
Study 28207430 — intervention group
Group type: COMPARATOR
Intervention: Central venous pressure
Number of subjects: 49
Study 28207791 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations of 40 to 49.99 nmol/L
Number of subjects: 26916
Study 28207791 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations of 30 to 39.99 nmol/L
Number of subjects: 26916
Study 28207791 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations of <30 nmol/L
Number of subjects: 26916
Study 28207791 — intervention group
Group type: COMPARATOR
Intervention: 25(OH)D concentrations of 75 to 99.99 nmol/L
Number of subjects: 26916
Study 28207791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular mortality
Number of subjects: 26916
Study 28207791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer mortality
Number of subjects: 26916
Study 28207791 — intervention group
Group type: EXPERIMENTAL
Intervention: High 25(OH)D levels up to 125 nmol/L
Number of subjects: 26916
Study 28207896 — intervention group
Group type: EXPERIMENTAL
Intervention: Granzyme A-/- mice
Number of subjects: 0
Study 28207896 — intervention group
Group type: EXPERIMENTAL
Intervention: Granzyme K-/- mice
Number of subjects: 0
Study 28207896 — intervention group
Group type: COMPARATOR
Intervention: Granzyme B-/- mice
Number of subjects: 0
Study 28207896 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with Serpinb6b (granzyme A inhibitor)
Number of subjects: 0
Study 28207896 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-human primates post CHIKV infection
Number of subjects: 0
Study 28207896 — intervention group
Group type: EXPERIMENTAL
Intervention: Small cohort of human CHIKV patients
Number of subjects: 0
Study 28209184 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular closure device (VCD) used after PCI
Number of subjects: 200
Study 28209184 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VCD) not explicitly mentioned
Number of subjects: 200
Study 28209218 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC (non-vitamin K antagonist oral anticoagulants)
Number of subjects: 15641
Study 28209559 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 20
Study 28209559 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) and contrast-enhanced ultrasound (CEUS)
Number of subjects: 20
Study 28209559 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT), CEUS, and MRI
Number of subjects: 20
Study 28209597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (40%): Increased ankle eversion, external rotation, knee internal rotation, and greater knee work.
Number of subjects: 322
Study 28209597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (15%): Increased hip flexion, pelvis contralateral drop, thorax tilt, and increased hip work.
Number of subjects: 322
Study 28209597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (45%): High ankle dorsiflexion, thorax contralateral drop, ankle work, and prolonged ground contact time.
Number of subjects: 322
Study 28209597 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings: No correlation between movement clusters and clinically palpated location of pain.
Number of subjects: 322
Study 28210662 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 40 mg/mL 3-times-weekly formulation (GA40)
Number of subjects: 0
Study 28210927 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus peginterferon alfa-2a/ribavirin (PegIFN/RBV)
Number of subjects: 301
Study 28211448 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-5461
Number of subjects: 0
Study 28211448 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-3543
Number of subjects: 0
Study 28211448 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-5461 and CX-3543
Number of subjects: 0
Study 28212292 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 407
Study 28212292 — intervention group
Group type: COMPARATOR
Intervention: Conventional care regimens
Number of subjects: 407
Study 28212686 — intervention group
Group type: EXPERIMENTAL
Intervention: simplified overweight screening instrument without BMI calculation
Number of subjects: 168
Study 28212686 — intervention group
Group type: COMPARATOR
Intervention: 2007 World Health Organization Body Mass Index (BMI)-for-age reference Tables
Number of subjects: 168
Study 28212684 — intervention group
Group type: EXPERIMENTAL
Intervention: RENAPE observational registry
Number of subjects: 0
Study 28212993 — intervention group
Group type: EXPERIMENTAL
Intervention: gefitinib (250mg/day)
Number of subjects: 186
Study 28212993 — intervention group
Group type: COMPARATOR
Intervention: carboplatin/paclitaxel
Number of subjects: 186
Study 28213002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (500mg/day for 5 days on, 2 days off in 28-day cycles)
Number of subjects: 12
Study 28213002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 12
Study 28213204 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster eating rates
Number of subjects: 386
Study 28213204 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with overweight
Number of subjects: 386
Study 28213204 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating behaviours
Number of subjects: 386
Study 28213480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 22
Study 28213480 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 22
Study 28213480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 22
Study 28213480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28213596 — intervention group
Group type: EXPERIMENTAL
Intervention: Total white cell count (WBC) within the normal range (8.65-10.05×10^9/L)
Number of subjects: 880988
Study 28213596 — intervention group
Group type: EXPERIMENTAL
Intervention: High WBC within the reference range
Number of subjects: 880988
Study 28213664 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study 28213684 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based chronic care overweight and obesity treatment
Number of subjects: 477
Study 28213781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) before NAST
Number of subjects: 224
Study 28213914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic autonomic regulation therapy (ART) with vagus nerve stimulation (VNS) at 10 Hz, 250 μs pulse width, 18% duty cycle, maximum tolerable current amplitude after 10 weeks of titration
Number of subjects: 21
Study 28213914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic autonomic regulation therapy (ART) with vagus nerve stimulation (VNS)
Number of subjects: 21
Study 28213914 — intervention group
Group type: COMPARATOR
Intervention: Patients with symptomatic heart failure
Number of subjects: 21
Study 28213943 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab (10 mg/kg, accelerated infusion over ∼1 h), combined with lenalidomide (25 mg daily, Days 1-21) and dexamethasone (28 mg orally and 8 mg intravenously, weekly, Cycles 1-2; 40 mg orally, weekly, Cycles 3+)
Number of subjects: 70
Study 28213943 — intervention group
Group type: COMPARATOR
Intervention: Elotuzumab (10 mg/kg, standard infusion over ∼3 h), combined with lenalidomide and dexamethasone (from previous phase 3 study)
Number of subjects: 70
Study 28214655 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin treatment
Number of subjects: 65
Study 28214792 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 levels measured in HFpEF patients
Number of subjects: 174
Study 28214794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (LLT) for those with ≥3% 5-year absolute major cardiovascular events risk reduction (ARR)
Number of subjects: 10000
Study 28214794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive LLT for those with ≥2.3% ARR
Number of subjects: 10000
Study 28214794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive LLT for those with ≥1.5% ARR
Number of subjects: 10000
Study 28214794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive LLT for all coronary artery disease patients
Number of subjects: 10000
Study 28214794 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit-based treatment
Number of subjects: 10000
Study 28214794 — intervention group
Group type: COMPARATOR
Intervention: Standard LLT for all (reference strategy)
Number of subjects: 10000
Study 28215251 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption in T allele carriers
Number of subjects: 0
Study 28215251 — intervention group
Group type: COMPARATOR
Intervention: Caffeine consumption in CC genotype
Number of subjects: 0
Study 28215851 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Stereotactic Body Radiotherapy (SBRT) at escalating doses (35, 40, 45, and 50 Gy) in 10 daily fractions
Number of subjects: 20
Study 28215937 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneously monthly (or every 2 weeks if on apheresis)
Number of subjects: 106
Study 28215937 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (increased dosing to every 2 weeks)
Number of subjects: 106
Study 28215937 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (in patients on apheresis)
Number of subjects: 106
Study 28215937 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 106
Study 28216350 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-coded quantitative digital subtraction angiography (CQDSA)
Number of subjects: 35
Study 28216350 — intervention group
Group type: EXPERIMENTAL
Intervention: TTP ≤5 seconds
Number of subjects: 35
Study 28216350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-type endoleak
Number of subjects: 35
Study 28216359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated endovascular aneurysm repair (FEVAR)
Number of subjects: 85
Study 28218593 — intervention group
Group type: EXPERIMENTAL
Intervention: In-car video feedback intervention (3 months of intervention with weekly reports, DVD of unsafe events, and telephone contacts)
Number of subjects: 12
Study 28218593 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention monitoring (3 months)
Number of subjects: 12
Study 28218593 — intervention group
Group type: EXPERIMENTAL
Intervention: In-car video feedback intervention
Number of subjects: 12
Study 28218593 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention monitoring
Number of subjects: 12
Study 28218598 — intervention group
Group type: EXPERIMENTAL
Intervention: VISION COACH™ interactive light board
Number of subjects: 0
Study 28218598 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Object Detection
Number of subjects: 0
Study 28219323 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Protector™
Number of subjects: 26
Study 28219331 — intervention group
Group type: EXPERIMENTAL
Intervention: Imago V-Blade®
Number of subjects: 42
Study 28219331 — intervention group
Group type: COMPARATOR
Intervention: Glidescope®
Number of subjects: 42
Study 28219399 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive cochlear microphonic (CM) phase monitoring
Number of subjects: 24
Study 28219399 — intervention group
Group type: COMPARATOR
Intervention: Invasive ICP monitoring
Number of subjects: 24
Study 28219443 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 0
Study 28219443 — intervention group
Group type: COMPARATOR
Intervention: Total splenectomy
Number of subjects: 0
Study 28219694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg per day for 21 of 28 days until lymphoma progression or unacceptable toxicity
Number of subjects: 48
Study 28219694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 48
Study 28219916 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse-wave velocity (cf-PWV)
Number of subjects: 1599
Study 28219916 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial-ankle pulse-wave velocity (ba-PWV)
Number of subjects: 1599
Study 28219916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cf-PWV and ba-PWV
Number of subjects: 1599
Study 28219925 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent long-term heavy alcohol intake >112 g of ethanol/week
Number of subjects: 3869
Study 28219925 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal variability in alcohol consumption
Number of subjects: 3869
Study 28220197 — intervention group
Group type: EXPERIMENTAL
Intervention: EWGSOP definition
Number of subjects: 965
Study 28220197 — intervention group
Group type: EXPERIMENTAL
Intervention: IWGS definition
Number of subjects: 965
Study 28220197 — intervention group
Group type: EXPERIMENTAL
Intervention: FNIH definition
Number of subjects: 965
Study 28220197 — intervention group
Group type: EXPERIMENTAL
Intervention: EWGSOP + body fat >25%
Number of subjects: 965
Study 28220197 — intervention group
Group type: EXPERIMENTAL
Intervention: IWGS + body fat >30%
Number of subjects: 965
Study 28221201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronto-7™ (Masimo Corporation)
Number of subjects: 44
Study 28221201 — intervention group
Group type: EXPERIMENTAL
Intervention: NBM-200MP™ (OrSense Ltd)
Number of subjects: 44
Study 28221206 — intervention group
Group type: EXPERIMENTAL
Intervention: New pathological Q waves (anterior) in V1 to V5
Number of subjects: 1464
Study 28221206 — intervention group
Group type: EXPERIMENTAL
Intervention: New pathological Q waves (any location)
Number of subjects: 1464
Study 28221206 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (n=1464)
Number of subjects: 1464
Study 28221206 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite or probable new pathological Q waves
Number of subjects: 1464
Study 28221298 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM
Number of subjects: 42
Study 28221298 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 42
Study 28221298 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-proADM and PCT
Number of subjects: 42
Study 28221823 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed 640G 'suspend before low' feature set at 65 mg/dL, predicting hypoglycemia and suspending insulin delivery when glucose was predicted to be ≤85 mg/dL.
Number of subjects: 69
Study 28221823 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed 640G 'suspend before low' feature
Number of subjects: 69
Study 28221867 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 201